Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28300254 | 0.81 | ENPP2 (0.46) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL6267276 | 0.81 | MAPT (0.42) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL10547556 | 0.79 | HTR2C (0.56) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL237972 | 0.79 | ENPP2 (0.63) | ENPP2MMP3KDM4ETDP1MEN1 | |
| Benzene SCHEMBL5438521 | 0.77 | ENPP2 (0.61) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL11154063 | 0.77 | ENPP2 (0.45) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL11155035 | 0.77 | ENPP2 (0.45) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL3020802 | 0.76 | AR (0.47) | ENPP2MMP3KDM4ETDP1MEN1 | |
| SCHEMBL5022962 | 0.75 | SIGMAR1 (0.50) | MEN1KMT2AMAPTRECQL | |
| SCHEMBL3272193 | 0.75 | SLC6A4 (0.47) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-08-07 | — | — | US | disclosed |
| CN-115151553-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4519246-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | Prilenia Neurotherapeutics Ltd. (IL) | 2025-03-12 | — | — | EP | disclosed |
| CN-119137100-A | Process and intermediates for the preparation of pridopidine | 普瑞尼亚神经治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023214412-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | WO | disclosed |
| CN-115151553-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021143923-A1 | BORONIC ACID DERIVATIVES | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | disclosed |
| EP-2164825-B1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| CN-101679191-B | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS SPA | 2014-03-12 | — | — | CN | disclosed |
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2164825-A1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008148468-A1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| US-6812228-B2 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE MOVEMENT DISORDERS CHARACTERIZED BY HYPOKINESIA, TREMOR, AND MUSCULAR RIGIDITY | WARNER-LAMBERT COMPANY | 2004-11-02 | — | — | US | disclosed |
| EP-1282625-B1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER LAMBERT CO (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030220335-A1 | Benzoxazines for use in the treatment of parkinson's disease | WARNER-LAMBERT COMPANY | 2003-11-27 | — | — | US | disclosed |
| EP-1282625-A1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER-LAMBERT COMPANY (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001085734-A1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| US-5405826-A | Herbicidal pyridopyridazinones and pyridopyridazinethiones | RHONE POULENC AGRICULTURE LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| EP-0555957-A1 | Pyrido 2,3-d pyridazine derivatives as herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A2, RYR2 | ENPP2 1052/4885MMP3 4671/4885KDM4E 2822/4885 |
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | QDPR, MAOB, DRD2 | ENPP2 2535/4885MMP3 3718/4885KDM4E 2968/4885 |
| US-20030220335-A1 | Benzoxazines for use in the treatment of parkinson's disease | PARK7, HAX1, SNCA | ENPP2 743/4885MMP3 606/4885KDM4E 2991/4885 |
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | GLS2, RECQL, PYGL | ENPP2 2131/4885MMP3 4124/4885KDM4E 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.